GICS Sector : Healthcare
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates.The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
Inhibrx Biosciences (NASDAQ:INBX) Reaches New 52-Week High – Here’s Why
Dec -05
Stock Traders Buy High Volume of Inhibrx Biosciences Call Options (NASDAQ:INBX)
Nov -15
Inhibrx Reports Third Quarter 2025 Financial Results
Nov -14
Inhibrx Announces Participation in Upcoming Scientific Conferences
Nov -04
Ethic Inc. Purchases New Shares in Inhibrx Biosciences, Inc. $INBX
Oct -31
Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing
Oct -24
Inhibrx shares surge after bone cancer drug slows disease progression in trial
Oct -23
Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
Oct -23
Inhibrx's biological therapeutic candidates exhibit strong growth driven by increasing demand for innovative treatments, strategic partnerships, and a robust pipeline of novel antibodies. The company's focus on rare diseases and cancer therapies, coupled with its proprietary single-domain antibody platform, positions it for continued growth and market expansion.
A novel, tetravalent, bispecific antibody targeting PD-1 and 4-1BB, designed to enhance anti-tumor activity and reduce immune-related adverse events.
A novel, tetravalent, bispecific antibody targeting PD-1 and OX40, designed to enhance anti-tumor activity and reduce immune-related adverse events.
A novel, tetravalent, bispecific antibody targeting PD-1 and GITR, designed to enhance anti-tumor activity and reduce immune-related adverse events.
A novel, tetravalent, bispecific antibody targeting PD-1 and CD137, designed to enhance anti-tumor activity and reduce immune-related adverse events.
Inhibrx, Inc. has a moderate threat of substitutes due to the availability of alternative treatments and therapies for the diseases they are targeting.
Inhibrx, Inc. has a low bargaining power of customers due to the specialized nature of their products and the lack of alternative options for patients.
Inhibrx, Inc. has a moderate bargaining power of suppliers due to the availability of multiple suppliers for raw materials and equipment.
Inhibrx, Inc. has a high threat of new entrants due to the growing interest in biotechnology and the availability of funding for startups.
Inhibrx, Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry.
| Value | |
|---|---|
| Debt Weight | 82.77% |
| Debt Cost | 15.15% |
| Equity Weight | 17.23% |
| Equity Cost | 18.34% |
| WACC | 15.70% |
| Leverage | 480.50% |
Value: 8.8
Growth: 6.2
Quality: 5.1
Yield: 6.0
Momentum: 10.0
Volatility: 0.3
1-Year Total Return ->
Value: 8.2
Growth: 3.6
Quality: 6.5
Yield: 0.0
Momentum: 10.0
Volatility: 1.3
1-Year Total Return ->
Value: 6.2
Growth: 6.0
Quality: 4.6
Yield: 0.0
Momentum: 9.5
Volatility: 1.0
1-Year Total Return ->
Value: 9.0
Growth: 2.0
Quality: 4.4
Yield: 0.0
Momentum: 6.0
Volatility: 4.0
1-Year Total Return ->
Value: 6.0
Growth: 3.3
Quality: 3.3
Yield: 0.0
Momentum: 10.0
Volatility: 0.3
1-Year Total Return ->
Value: 7.2
Growth: 4.6
Quality: 3.1
Yield: 0.0
Momentum: 0.5
Volatility: 2.0
1-Year Total Return ->